CovidChloroV1, Main, Exploration, bibRecordById, pubmed:32809918

Oxytocin's anti-inflammatory and proimmune functions in COVID-19: a transcriptomic signature-based approach.

Identifieur interne : 000E89 ( Main/Exploration ); précédent : 000E88; suivant : 000E90

Oxytocin's anti-inflammatory and proimmune functions in COVID-19: a transcriptomic signature-based approach.

Auteurs : Ali S. Imami [États-Unis] ; Sinead M. O'Donovan [États-Unis] ; Justin F. Creeden [États-Unis] ; Xiaojun Wu [États-Unis] ; Hunter Eby [États-Unis] ; Cheryl B. Mccullumsmith [États-Unis] ; Kerstin Uvn S-Moberg [Suède] ; Robert E. Mccullumsmith [États-Unis] ; Elissar Andari [États-Unis]

Source :

Physiological genomics [ 1531-2267 ] ; 2020.

RBID : pubmed:32809918

Descripteurs français

KwdFr :
- Analyse de profil d'expression de gènes (MeSH), Anti-inflammatoires (pharmacologie), Bases de données génétiques (MeSH), Betacoronavirus (effets des médicaments et des substances chimiques), Betacoronavirus (immunologie), Humains (MeSH), Immunité acquise (effets des médicaments et des substances chimiques), Immunité acquise (génétique), Infections à coronavirus (génétique), Infections à coronavirus (immunologie), Infections à coronavirus (traitement médicamenteux), Infections à coronavirus (virologie), Interactions hôte-pathogène (MeSH), Lignée cellulaire (MeSH), Lymphocytes T (effets des médicaments et des substances chimiques), Lymphocytes T (immunologie), Lymphocytes T (virologie), Ocytocine (analogues et dérivés), Ocytocine (pharmacologie), Pandémies (MeSH), Pneumopathie virale (génétique), Pneumopathie virale (immunologie), Pneumopathie virale (traitement médicamenteux), Pneumopathie virale (virologie), Transcriptome (MeSH).
MESH :
- analogues et dérivés : Ocytocine.
- effets des médicaments et des substances chimiques : Betacoronavirus, Immunité acquise, Lymphocytes T.
- génétique : Immunité acquise, Infections à coronavirus, Pneumopathie virale.
- immunologie : Betacoronavirus, Infections à coronavirus, Lymphocytes T, Pneumopathie virale.
- pharmacologie : Anti-inflammatoires, Ocytocine.
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- virologie : Infections à coronavirus, Lymphocytes T, Pneumopathie virale.
- Analyse de profil d'expression de gènes, Bases de données génétiques, Humains, Interactions hôte-pathogène, Lignée cellulaire, Pandémies, Transcriptome.

English descriptors

KwdEn :
- Adaptive Immunity (drug effects), Adaptive Immunity (genetics), Anti-Inflammatory Agents (pharmacology), Betacoronavirus (drug effects), Betacoronavirus (immunology), COVID-19 (MeSH), Cell Line (MeSH), Coronavirus Infections (drug therapy), Coronavirus Infections (genetics), Coronavirus Infections (immunology), Coronavirus Infections (virology), Databases, Genetic (MeSH), Gene Expression Profiling (MeSH), Host-Pathogen Interactions (MeSH), Humans (MeSH), Oxytocin (analogs & derivatives), Oxytocin (pharmacology), Pandemics (MeSH), Pneumonia, Viral (drug therapy), Pneumonia, Viral (genetics), Pneumonia, Viral (immunology), Pneumonia, Viral (virology), SARS-CoV-2 (MeSH), T-Lymphocytes (drug effects), T-Lymphocytes (immunology), T-Lymphocytes (virology), Transcriptome (MeSH).
MESH :
- chemical , analogs & derivatives : Oxytocin.
- chemical , pharmacology : Anti-Inflammatory Agents, Oxytocin.
- drug effects : Adaptive Immunity, Betacoronavirus, T-Lymphocytes.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- genetics : Adaptive Immunity, Coronavirus Infections, Pneumonia, Viral.
- immunology : Betacoronavirus, Coronavirus Infections, Pneumonia, Viral, T-Lymphocytes.
- virology : Coronavirus Infections, Pneumonia, Viral, T-Lymphocytes.
- COVID-19, Cell Line, Databases, Genetic, Gene Expression Profiling, Host-Pathogen Interactions, Humans, Pandemics, SARS-CoV-2, Transcriptome.

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a worldwide pandemic, infecting over 16 million people worldwide with a significant mortality rate. However, there is no current Food and Drug Administration-approved drug that treats coronavirus disease 2019 (COVID-19). Damage to T lymphocytes along with the cytokine storm are important factors that lead to exacerbation of clinical cases. Here, we are proposing intravenous oxytocin (OXT) as a candidate for adjunctive therapy for COVID-19. OXT has anti-inflammatory and proimmune adaptive functions. Using the Library of Integrated Network-Based Cellular Signatures (LINCS), we used the transcriptomic signature for carbetocin, an OXT agonist, and compared it to gene knockdown signatures of inflammatory (such as interleukin IL-1β and IL-6) and proimmune markers (including T cell and macrophage cell markers like CD40 and ARG1). We found that carbetocin's transcriptomic signature has a pattern of concordance with inflammation and immune marker knockdown signatures that are consistent with reduction of inflammation and promotion and sustaining of immune response. This suggests that carbetocin may have potent effects in modulating inflammation, attenuating T cell inhibition, and enhancing T cell activation. Our results also suggest that carbetocin is more effective at inducing immune cell responses than either lopinavir or hydroxychloroquine, both of which have been explored for the treatment of COVID-19.

DOI: 10.1152/physiolgenomics.00095.2020
PubMed: 32809918
PubMed Central: PMC7877479

Affiliations:

Suède, États-Unis
Ohio

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000E66
to stream Main, to step Curation: 000E66

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Oxytocin's anti-inflammatory and proimmune functions in COVID-19: a transcriptomic signature-based approach.</title>
<author><name sortKey="Imami, Ali S" sort="Imami, Ali S" uniqKey="Imami A" first="Ali S" last="Imami">Ali S. Imami</name>
<affiliation wicri:level="2"><nlm:affiliation>University of Toledo, Department of Neurosciences, College of Medicine and Life Sciences, Toledo, Ohio.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Ohio</region>
</placeName>
<wicri:cityArea>University of Toledo, Department of Neurosciences, College of Medicine and Life Sciences, Toledo</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="O Donovan, Sinead M" sort="O Donovan, Sinead M" uniqKey="O Donovan S" first="Sinead M" last="O'Donovan">Sinead M. O'Donovan</name>
<affiliation wicri:level="2"><nlm:affiliation>University of Toledo, Department of Neurosciences, College of Medicine and Life Sciences, Toledo, Ohio.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Ohio</region>
</placeName>
<wicri:cityArea>University of Toledo, Department of Neurosciences, College of Medicine and Life Sciences, Toledo</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Creeden, Justin F" sort="Creeden, Justin F" uniqKey="Creeden J" first="Justin F" last="Creeden">Justin F. Creeden</name>
<affiliation wicri:level="2"><nlm:affiliation>University of Toledo, Department of Neurosciences, College of Medicine and Life Sciences, Toledo, Ohio.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Ohio</region>
</placeName>
<wicri:cityArea>University of Toledo, Department of Neurosciences, College of Medicine and Life Sciences, Toledo</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Wu, Xiaojun" sort="Wu, Xiaojun" uniqKey="Wu X" first="Xiaojun" last="Wu">Xiaojun Wu</name>
<affiliation wicri:level="2"><nlm:affiliation>University of Toledo, Department of Neurosciences, College of Medicine and Life Sciences, Toledo, Ohio.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Ohio</region>
</placeName>
<wicri:cityArea>University of Toledo, Department of Neurosciences, College of Medicine and Life Sciences, Toledo</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Eby, Hunter" sort="Eby, Hunter" uniqKey="Eby H" first="Hunter" last="Eby">Hunter Eby</name>
<affiliation wicri:level="2"><nlm:affiliation>University of Toledo, Department of Neurosciences, College of Medicine and Life Sciences, Toledo, Ohio.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Ohio</region>
</placeName>
<wicri:cityArea>University of Toledo, Department of Neurosciences, College of Medicine and Life Sciences, Toledo</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Mccullumsmith, Cheryl B" sort="Mccullumsmith, Cheryl B" uniqKey="Mccullumsmith C" first="Cheryl B" last="Mccullumsmith">Cheryl B. Mccullumsmith</name>
<affiliation wicri:level="2"><nlm:affiliation>University of Toledo, Department of Psychiatry, College of Medicine and Life Sciences, Toledo, Ohio.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Ohio</region>
</placeName>
<wicri:cityArea>University of Toledo, Department of Psychiatry, College of Medicine and Life Sciences, Toledo</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Uvn S Moberg, Kerstin" sort="Uvn S Moberg, Kerstin" uniqKey="Uvn S Moberg K" first="Kerstin" last="Uvn S-Moberg">Kerstin Uvn S-Moberg</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Animal Environment and Health, Swedish University of Agricultural Sciences, Skara, Sweden.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Department of Animal Environment and Health, Swedish University of Agricultural Sciences, Skara</wicri:regionArea>
<wicri:noRegion>Skara</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mccullumsmith, Robert E" sort="Mccullumsmith, Robert E" uniqKey="Mccullumsmith R" first="Robert E" last="Mccullumsmith">Robert E. Mccullumsmith</name>
<affiliation wicri:level="2"><nlm:affiliation>University of Toledo, Department of Neurosciences, College of Medicine and Life Sciences, Toledo, Ohio.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Ohio</region>
</placeName>
<wicri:cityArea>University of Toledo, Department of Neurosciences, College of Medicine and Life Sciences, Toledo</wicri:cityArea>
</affiliation>
<affiliation wicri:level="2"><nlm:affiliation>Neurosciences Institute, ProMedica, Toledo, Ohio.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Ohio</region>
</placeName>
<wicri:cityArea>Neurosciences Institute, ProMedica, Toledo</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Andari, Elissar" sort="Andari, Elissar" uniqKey="Andari E" first="Elissar" last="Andari">Elissar Andari</name>
<affiliation wicri:level="2"><nlm:affiliation>University of Toledo, Department of Psychiatry, College of Medicine and Life Sciences, Toledo, Ohio.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Ohio</region>
</placeName>
<wicri:cityArea>University of Toledo, Department of Psychiatry, College of Medicine and Life Sciences, Toledo</wicri:cityArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32809918</idno>
<idno type="pmid">32809918</idno>
<idno type="doi">10.1152/physiolgenomics.00095.2020</idno>
<idno type="pmc">PMC7877479</idno>
<idno type="wicri:Area/Main/Corpus">000E66</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000E66</idno>
<idno type="wicri:Area/Main/Curation">000E66</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000E66</idno>
<idno type="wicri:Area/Main/Exploration">000E66</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Oxytocin's anti-inflammatory and proimmune functions in COVID-19: a transcriptomic signature-based approach.</title>
<author><name sortKey="Imami, Ali S" sort="Imami, Ali S" uniqKey="Imami A" first="Ali S" last="Imami">Ali S. Imami</name>
<affiliation wicri:level="2"><nlm:affiliation>University of Toledo, Department of Neurosciences, College of Medicine and Life Sciences, Toledo, Ohio.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Ohio</region>
</placeName>
<wicri:cityArea>University of Toledo, Department of Neurosciences, College of Medicine and Life Sciences, Toledo</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="O Donovan, Sinead M" sort="O Donovan, Sinead M" uniqKey="O Donovan S" first="Sinead M" last="O'Donovan">Sinead M. O'Donovan</name>
<affiliation wicri:level="2"><nlm:affiliation>University of Toledo, Department of Neurosciences, College of Medicine and Life Sciences, Toledo, Ohio.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Ohio</region>
</placeName>
<wicri:cityArea>University of Toledo, Department of Neurosciences, College of Medicine and Life Sciences, Toledo</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Creeden, Justin F" sort="Creeden, Justin F" uniqKey="Creeden J" first="Justin F" last="Creeden">Justin F. Creeden</name>
<affiliation wicri:level="2"><nlm:affiliation>University of Toledo, Department of Neurosciences, College of Medicine and Life Sciences, Toledo, Ohio.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Ohio</region>
</placeName>
<wicri:cityArea>University of Toledo, Department of Neurosciences, College of Medicine and Life Sciences, Toledo</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Wu, Xiaojun" sort="Wu, Xiaojun" uniqKey="Wu X" first="Xiaojun" last="Wu">Xiaojun Wu</name>
<affiliation wicri:level="2"><nlm:affiliation>University of Toledo, Department of Neurosciences, College of Medicine and Life Sciences, Toledo, Ohio.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Ohio</region>
</placeName>
<wicri:cityArea>University of Toledo, Department of Neurosciences, College of Medicine and Life Sciences, Toledo</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Eby, Hunter" sort="Eby, Hunter" uniqKey="Eby H" first="Hunter" last="Eby">Hunter Eby</name>
<affiliation wicri:level="2"><nlm:affiliation>University of Toledo, Department of Neurosciences, College of Medicine and Life Sciences, Toledo, Ohio.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Ohio</region>
</placeName>
<wicri:cityArea>University of Toledo, Department of Neurosciences, College of Medicine and Life Sciences, Toledo</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Mccullumsmith, Cheryl B" sort="Mccullumsmith, Cheryl B" uniqKey="Mccullumsmith C" first="Cheryl B" last="Mccullumsmith">Cheryl B. Mccullumsmith</name>
<affiliation wicri:level="2"><nlm:affiliation>University of Toledo, Department of Psychiatry, College of Medicine and Life Sciences, Toledo, Ohio.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Ohio</region>
</placeName>
<wicri:cityArea>University of Toledo, Department of Psychiatry, College of Medicine and Life Sciences, Toledo</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Uvn S Moberg, Kerstin" sort="Uvn S Moberg, Kerstin" uniqKey="Uvn S Moberg K" first="Kerstin" last="Uvn S-Moberg">Kerstin Uvn S-Moberg</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Animal Environment and Health, Swedish University of Agricultural Sciences, Skara, Sweden.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Department of Animal Environment and Health, Swedish University of Agricultural Sciences, Skara</wicri:regionArea>
<wicri:noRegion>Skara</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mccullumsmith, Robert E" sort="Mccullumsmith, Robert E" uniqKey="Mccullumsmith R" first="Robert E" last="Mccullumsmith">Robert E. Mccullumsmith</name>
<affiliation wicri:level="2"><nlm:affiliation>University of Toledo, Department of Neurosciences, College of Medicine and Life Sciences, Toledo, Ohio.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Ohio</region>
</placeName>
<wicri:cityArea>University of Toledo, Department of Neurosciences, College of Medicine and Life Sciences, Toledo</wicri:cityArea>
</affiliation>
<affiliation wicri:level="2"><nlm:affiliation>Neurosciences Institute, ProMedica, Toledo, Ohio.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Ohio</region>
</placeName>
<wicri:cityArea>Neurosciences Institute, ProMedica, Toledo</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Andari, Elissar" sort="Andari, Elissar" uniqKey="Andari E" first="Elissar" last="Andari">Elissar Andari</name>
<affiliation wicri:level="2"><nlm:affiliation>University of Toledo, Department of Psychiatry, College of Medicine and Life Sciences, Toledo, Ohio.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Ohio</region>
</placeName>
<wicri:cityArea>University of Toledo, Department of Psychiatry, College of Medicine and Life Sciences, Toledo</wicri:cityArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Physiological genomics</title>
<idno type="eISSN">1531-2267</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adaptive Immunity (drug effects)</term>
<term>Adaptive Immunity (genetics)</term>
<term>Anti-Inflammatory Agents (pharmacology)</term>
<term>Betacoronavirus (drug effects)</term>
<term>Betacoronavirus (immunology)</term>
<term>COVID-19 (MeSH)</term>
<term>Cell Line (MeSH)</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Coronavirus Infections (genetics)</term>
<term>Coronavirus Infections (immunology)</term>
<term>Coronavirus Infections (virology)</term>
<term>Databases, Genetic (MeSH)</term>
<term>Gene Expression Profiling (MeSH)</term>
<term>Host-Pathogen Interactions (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Oxytocin (analogs & derivatives)</term>
<term>Oxytocin (pharmacology)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (drug therapy)</term>
<term>Pneumonia, Viral (genetics)</term>
<term>Pneumonia, Viral (immunology)</term>
<term>Pneumonia, Viral (virology)</term>
<term>SARS-CoV-2 (MeSH)</term>
<term>T-Lymphocytes (drug effects)</term>
<term>T-Lymphocytes (immunology)</term>
<term>T-Lymphocytes (virology)</term>
<term>Transcriptome (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Analyse de profil d'expression de gènes (MeSH)</term>
<term>Anti-inflammatoires (pharmacologie)</term>
<term>Bases de données génétiques (MeSH)</term>
<term>Betacoronavirus (effets des médicaments et des substances chimiques)</term>
<term>Betacoronavirus (immunologie)</term>
<term>Humains (MeSH)</term>
<term>Immunité acquise (effets des médicaments et des substances chimiques)</term>
<term>Immunité acquise (génétique)</term>
<term>Infections à coronavirus (génétique)</term>
<term>Infections à coronavirus (immunologie)</term>
<term>Infections à coronavirus (traitement médicamenteux)</term>
<term>Infections à coronavirus (virologie)</term>
<term>Interactions hôte-pathogène (MeSH)</term>
<term>Lignée cellulaire (MeSH)</term>
<term>Lymphocytes T (effets des médicaments et des substances chimiques)</term>
<term>Lymphocytes T (immunologie)</term>
<term>Lymphocytes T (virologie)</term>
<term>Ocytocine (analogues et dérivés)</term>
<term>Ocytocine (pharmacologie)</term>
<term>Pandémies (MeSH)</term>
<term>Pneumopathie virale (génétique)</term>
<term>Pneumopathie virale (immunologie)</term>
<term>Pneumopathie virale (traitement médicamenteux)</term>
<term>Pneumopathie virale (virologie)</term>
<term>Transcriptome (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Oxytocin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Anti-Inflammatory Agents</term>
<term>Oxytocin</term>
</keywords>
<keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Ocytocine</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Adaptive Immunity</term>
<term>Betacoronavirus</term>
<term>T-Lymphocytes</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Betacoronavirus</term>
<term>Immunité acquise</term>
<term>Lymphocytes T</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Adaptive Immunity</term>
<term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Immunité acquise</term>
<term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Betacoronavirus</term>
<term>Infections à coronavirus</term>
<term>Lymphocytes T</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Betacoronavirus</term>
<term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
<term>T-Lymphocytes</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Anti-inflammatoires</term>
<term>Ocytocine</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Lymphocytes T</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
<term>T-Lymphocytes</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>COVID-19</term>
<term>Cell Line</term>
<term>Databases, Genetic</term>
<term>Gene Expression Profiling</term>
<term>Host-Pathogen Interactions</term>
<term>Humans</term>
<term>Pandemics</term>
<term>SARS-CoV-2</term>
<term>Transcriptome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Analyse de profil d'expression de gènes</term>
<term>Bases de données génétiques</term>
<term>Humains</term>
<term>Interactions hôte-pathogène</term>
<term>Lignée cellulaire</term>
<term>Pandémies</term>
<term>Transcriptome</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a worldwide pandemic, infecting over 16 million people worldwide with a significant mortality rate. However, there is no current Food and Drug Administration-approved drug that treats coronavirus disease 2019 (COVID-19). Damage to T lymphocytes along with the cytokine storm are important factors that lead to exacerbation of clinical cases. Here, we are proposing intravenous oxytocin (OXT) as a candidate for adjunctive therapy for COVID-19. OXT has anti-inflammatory and proimmune adaptive functions. Using the Library of Integrated Network-Based Cellular Signatures (LINCS), we used the transcriptomic signature for carbetocin, an OXT agonist, and compared it to gene knockdown signatures of inflammatory (such as interleukin IL-1β and IL-6) and proimmune markers (including T cell and macrophage cell markers like CD40 and ARG1). We found that carbetocin's transcriptomic signature has a pattern of concordance with inflammation and immune marker knockdown signatures that are consistent with reduction of inflammation and promotion and sustaining of immune response. This suggests that carbetocin may have potent effects in modulating inflammation, attenuating T cell inhibition, and enhancing T cell activation. Our results also suggest that carbetocin is more effective at inducing immune cell responses than either lopinavir or hydroxychloroquine, both of which have been explored for the treatment of COVID-19.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32809918</PMID>
<DateCompleted><Year>2020</Year>
<Month>09</Month>
<Day>16</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>02</Month>
<Day>23</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1531-2267</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>52</Volume>
<Issue>9</Issue>
<PubDate><Year>2020</Year>
<Month>09</Month>
<Day>01</Day>
</PubDate>
</JournalIssue>
<Title>Physiological genomics</Title>
<ISOAbbreviation>Physiol Genomics</ISOAbbreviation>
</Journal>
<ArticleTitle>Oxytocin's anti-inflammatory and proimmune functions in COVID-19: a transcriptomic signature-based approach.</ArticleTitle>
<Pagination><MedlinePgn>401-407</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1152/physiolgenomics.00095.2020</ELocationID>
<Abstract><AbstractText>The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a worldwide pandemic, infecting over 16 million people worldwide with a significant mortality rate. However, there is no current Food and Drug Administration-approved drug that treats coronavirus disease 2019 (COVID-19). Damage to T lymphocytes along with the cytokine storm are important factors that lead to exacerbation of clinical cases. Here, we are proposing intravenous oxytocin (OXT) as a candidate for adjunctive therapy for COVID-19. OXT has anti-inflammatory and proimmune adaptive functions. Using the Library of Integrated Network-Based Cellular Signatures (LINCS), we used the transcriptomic signature for carbetocin, an OXT agonist, and compared it to gene knockdown signatures of inflammatory (such as interleukin IL-1β and IL-6) and proimmune markers (including T cell and macrophage cell markers like CD40 and ARG1). We found that carbetocin's transcriptomic signature has a pattern of concordance with inflammation and immune marker knockdown signatures that are consistent with reduction of inflammation and promotion and sustaining of immune response. This suggests that carbetocin may have potent effects in modulating inflammation, attenuating T cell inhibition, and enhancing T cell activation. Our results also suggest that carbetocin is more effective at inducing immune cell responses than either lopinavir or hydroxychloroquine, both of which have been explored for the treatment of COVID-19.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Imami</LastName>
<ForeName>Ali S</ForeName>
<Initials>AS</Initials>
<AffiliationInfo><Affiliation>University of Toledo, Department of Neurosciences, College of Medicine and Life Sciences, Toledo, Ohio.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>O'Donovan</LastName>
<ForeName>Sinead M</ForeName>
<Initials>SM</Initials>
<AffiliationInfo><Affiliation>University of Toledo, Department of Neurosciences, College of Medicine and Life Sciences, Toledo, Ohio.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Creeden</LastName>
<ForeName>Justin F</ForeName>
<Initials>JF</Initials>
<AffiliationInfo><Affiliation>University of Toledo, Department of Neurosciences, College of Medicine and Life Sciences, Toledo, Ohio.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wu</LastName>
<ForeName>Xiaojun</ForeName>
<Initials>X</Initials>
<AffiliationInfo><Affiliation>University of Toledo, Department of Neurosciences, College of Medicine and Life Sciences, Toledo, Ohio.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Eby</LastName>
<ForeName>Hunter</ForeName>
<Initials>H</Initials>
<AffiliationInfo><Affiliation>University of Toledo, Department of Neurosciences, College of Medicine and Life Sciences, Toledo, Ohio.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>McCullumsmith</LastName>
<ForeName>Cheryl B</ForeName>
<Initials>CB</Initials>
<AffiliationInfo><Affiliation>University of Toledo, Department of Psychiatry, College of Medicine and Life Sciences, Toledo, Ohio.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Uvnäs-Moberg</LastName>
<ForeName>Kerstin</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>Department of Animal Environment and Health, Swedish University of Agricultural Sciences, Skara, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>McCullumsmith</LastName>
<ForeName>Robert E</ForeName>
<Initials>RE</Initials>
<AffiliationInfo><Affiliation>University of Toledo, Department of Neurosciences, College of Medicine and Life Sciences, Toledo, Ohio.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Neurosciences Institute, ProMedica, Toledo, Ohio.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Andari</LastName>
<ForeName>Elissar</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>University of Toledo, Department of Psychiatry, College of Medicine and Life Sciences, Toledo, Ohio.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>207014</GrantID>
<Agency>University of Toledo Medical Research Society</Agency>
<Country>International</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>08</Month>
<Day>18</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Physiol Genomics</MedlineTA>
<NlmUniqueID>9815683</NlmUniqueID>
<ISSNLinking>1094-8341</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>50-56-6</RegistryNumber>
<NameOfSubstance UI="D010121">Oxytocin</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>88TWF8015Y</RegistryNumber>
<NameOfSubstance UI="C020731">carbetocin</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D056704" MajorTopicYN="N">Adaptive Immunity</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D030541" MajorTopicYN="N">Databases, Genetic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020869" MajorTopicYN="Y">Gene Expression Profiling</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D054884" MajorTopicYN="N">Host-Pathogen Interactions</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010121" MajorTopicYN="N">Oxytocin</DescriptorName>
<QualifierName UI="Q000031" MajorTopicYN="Y">analogs & derivatives</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D059467" MajorTopicYN="N">Transcriptome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">COVID19</Keyword>
<Keyword MajorTopicYN="Y">LINCS</Keyword>
<Keyword MajorTopicYN="Y">immune</Keyword>
<Keyword MajorTopicYN="Y">oxytocin</Keyword>
<Keyword MajorTopicYN="Y">transcriptomic signature</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>8</Month>
<Day>19</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>9</Month>
<Day>17</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>8</Month>
<Day>19</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32809918</ArticleId>
<ArticleId IdType="doi">10.1152/physiolgenomics.00095.2020</ArticleId>
<ArticleId IdType="pmc">PMC7877479</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>J Infect Dis. 2020 May 11;221(11):1762-1769</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32227123</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Invest New Drugs. 2020 Dec;38(6):1888-1898</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32488569</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2019 Jul 1;203(1):3-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31209141</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunol Rev. 2020 May;295(1):68-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32166778</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Microbiol Mol Biol Rev. 2012 Mar;76(1):16-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22390970</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Infect Dis. 2004 Jul;8(4):223-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15234326</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Mol Immunol. 2013 Mar;10(2):103-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23241902</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Bioinformatics. 2007 Oct 25;8:412</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17961233</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Open Microbiol J. 2008;2:49-59</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19088911</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2005 Feb;79(3):1966-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15650225</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Menopause Int. 2011 Dec;17(4):120-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22120944</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11704-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9326674</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 May 7;382(19):1787-1799</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32187464</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Brief Bioinform. 2006 Dec;7(4):331-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17132622</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Endocr Disord. 2016 Jun 07;16(1):34</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27268060</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Sci (Lond). 2019 Sep 19;133(18):1977-1992</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31519790</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Physiol Endocrinol Metab. 2008 Sep;295(3):E686-91</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18593851</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunology. 2008 Jun;124(2):149-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18384356</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diabetes Metab. 2018 Jun;44(3):292-295</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29129540</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Physiol Rev. 2001 Apr;81(2):629-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11274341</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Pharmacol. 2017 Dec;57(12):1573-1581</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28679021</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Commun. 2016 Sep 26;7:12846</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27667448</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Post Reprod Health. 2017 Mar;23(1):6-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28381099</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Discov. 2020 Mar 18;6:16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32194981</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Pharmacol. 1985 Jun 7;112(2):203-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">4029259</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunol Rev. 2014 May;259(1):88-102</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24712461</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2017 Nov 30;171(6):1437-1452.e17</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29195078</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Rep. 2019 Feb 26;9(1):2836</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30808956</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Syst. 2018 Jan 24;6(1):13-24</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29199020</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Physiol Behav. 1996 Nov;60(5):1311-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8916187</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Psychoneuroendocrinology. 2004 Sep;29(8):1004-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15219651</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Cell. 2018 Apr 9;33(4):563-569</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29634944</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Peptides. 2001 Sep;22(9):1479-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11514032</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>EMBO Rep. 2018 Aug;19(8):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29880709</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Exp Dermatol. 2013 Jun;22(6):399-405</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23711064</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Drug Investig. 2018 Aug;38(8):653-671</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29737455</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Feb 15;395(10223):497-506</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31986264</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunometabolism. 2019 Jun 20;1(T Cell Metabolic Reprogramming):e190006</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31328019</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Endocrinology. 1999 Mar;140(3):1301-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10067857</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>EBioMedicine. 2020 May;55:102763</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32361250</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Biotechnol. 2006 Sep;24(9):1162-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17061323</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Innate Immun. 2020;12(5):387-398</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31851971</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Feb 15;395(10223):507-513</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32007143</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Bioinformatics. 2014 Jan 15;15:14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24423217</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Peptides. 1997;18(9):1377-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9392839</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Bioinformatics. 2005 Jul 15;6 Suppl 2:S12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16026597</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Surg Res. 2005 Jun 1;126(1):73-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15916978</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2013 Oct 30;8(10):e78898</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24205344</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2006 Sep 29;313(5795):1929-35</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17008526</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Zh Mikrobiol Epidemiol Immunobiol. 2010 Nov-Dec;(6):3-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21384587</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunobiology. 2019 May;224(3):449-454</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30772094</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Suède</li>
<li>États-Unis</li>
</country>
<region><li>Ohio</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Ohio"><name sortKey="Imami, Ali S" sort="Imami, Ali S" uniqKey="Imami A" first="Ali S" last="Imami">Ali S. Imami</name>
</region>
<name sortKey="Andari, Elissar" sort="Andari, Elissar" uniqKey="Andari E" first="Elissar" last="Andari">Elissar Andari</name>
<name sortKey="Creeden, Justin F" sort="Creeden, Justin F" uniqKey="Creeden J" first="Justin F" last="Creeden">Justin F. Creeden</name>
<name sortKey="Eby, Hunter" sort="Eby, Hunter" uniqKey="Eby H" first="Hunter" last="Eby">Hunter Eby</name>
<name sortKey="Mccullumsmith, Cheryl B" sort="Mccullumsmith, Cheryl B" uniqKey="Mccullumsmith C" first="Cheryl B" last="Mccullumsmith">Cheryl B. Mccullumsmith</name>
<name sortKey="Mccullumsmith, Robert E" sort="Mccullumsmith, Robert E" uniqKey="Mccullumsmith R" first="Robert E" last="Mccullumsmith">Robert E. Mccullumsmith</name>
<name sortKey="Mccullumsmith, Robert E" sort="Mccullumsmith, Robert E" uniqKey="Mccullumsmith R" first="Robert E" last="Mccullumsmith">Robert E. Mccullumsmith</name>
<name sortKey="O Donovan, Sinead M" sort="O Donovan, Sinead M" uniqKey="O Donovan S" first="Sinead M" last="O'Donovan">Sinead M. O'Donovan</name>
<name sortKey="Wu, Xiaojun" sort="Wu, Xiaojun" uniqKey="Wu X" first="Xiaojun" last="Wu">Xiaojun Wu</name>
</country>
<country name="Suède"><noRegion><name sortKey="Uvn S Moberg, Kerstin" sort="Uvn S Moberg, Kerstin" uniqKey="Uvn S Moberg K" first="Kerstin" last="Uvn S-Moberg">Kerstin Uvn S-Moberg</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E89 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000E89 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:32809918
   |texte=   Oxytocin's anti-inflammatory and proimmune functions in COVID-19: a transcriptomic signature-based approach.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:32809918" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidChloroV1

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021

	Serveur d'exploration COVID et hydrochloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration COVID et hydrochloroquine

Oxytocin's anti-inflammatory and proimmune functions in COVID-19: a transcriptomic signature-based approach.

Oxytocin's anti-inflammatory and proimmune functions in COVID-19: a transcriptomic signature-based approach.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki